Enrico N. De Toni

机构：Munich University of Applied Sciences, LMU Klinikum, Comprehensive Cancer Center Erlangen, Ludwig-Maximilians-Universität München · ORCID：0000-0002-8101-8207

发表论文 169 篇 · 总被引 7834 次 · h-index 38

代表论文

• Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies (2024 · JHEP Reports · 被引 19)
• Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial (2025 · Hepatology · 被引 16)
• Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study (2024 · European Journal of Cancer · 被引 13)
• Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab (2024 · JHEP Reports · 被引 11)
• Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort (2025 · Alimentary Pharmacology & Therapeutics · 被引 7)
• Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study (2025 · Cancers · 被引 7)